BACKGROUND & AIMS: Patient-reported outcomes (PROs) convey important aspects of health status, complementing physician-reported measures. The PRO Measurement Information System (PROMIS) provides valid, widely available measures applicable to patients with chronic illness and the general population. We sought to evaluate these measures in a large cohort of patients with inflammatory bowel disease (IBD). METHODS: By using data from the Crohn's and Colitis Foundation Association Partners internet cohort, we performed cross-sectional and longitudinal analyses to evaluate associations between PROMIS measures and validated disease activity indices (Short Crohn's Disease Activity Index and Simple Clinical Colitis Activity Index) and the Short IBD Questionnaire quality-of-life instrument. RESULTS: A total of 10,634 individuals (6689 with Crohn's disease and 3945 with ulcerative colitis or indeterminate colitis) completed PRO testing. Compared with the general population (mean PROMIS score, 50), IBD patients in this cohort reported more depression (mean, 54), anxiety (mean, 52), fatigue (mean, 56), sleep disturbance (mean, 52), and pain interference (mean, 53); and they had less social satisfaction (mean, 48). In each PROMIS domain, there was worse functioning with increasing levels of disease activity and worsening Short IBD Questionnaire scores (P < .001 for all). Longitudinal analyses showed improved PROMIS scores with improved disease activity and worsening PROMIS scores with worsening disease (P < .001 for all comparisons). CONCLUSIONS: In a cross-sectional and longitudinal study, we observed differences between patients with IBD and the general population in several important aspects of health. The improvement in diverse health outcome measures with improved disease control provides strong support for the construct validity of PROMIS measures in the IBD population. Their use should advance patient-centered outcomes research in IBD.
BACKGROUND & AIMS:Patient-reported outcomes (PROs) convey important aspects of health status, complementing physician-reported measures. The PRO Measurement Information System (PROMIS) provides valid, widely available measures applicable to patients with chronic illness and the general population. We sought to evaluate these measures in a large cohort of patients with inflammatory bowel disease (IBD). METHODS: By using data from the Crohn's and Colitis Foundation Association Partners internet cohort, we performed cross-sectional and longitudinal analyses to evaluate associations between PROMIS measures and validated disease activity indices (Short Crohn's Disease Activity Index and Simple Clinical Colitis Activity Index) and the Short IBD Questionnaire quality-of-life instrument. RESULTS: A total of 10,634 individuals (6689 with Crohn's disease and 3945 with ulcerative colitis or indeterminate colitis) completed PRO testing. Compared with the general population (mean PROMIS score, 50), IBD patients in this cohort reported more depression (mean, 54), anxiety (mean, 52), fatigue (mean, 56), sleep disturbance (mean, 52), and pain interference (mean, 53); and they had less social satisfaction (mean, 48). In each PROMIS domain, there was worse functioning with increasing levels of disease activity and worsening Short IBD Questionnaire scores (P < .001 for all). Longitudinal analyses showed improved PROMIS scores with improved disease activity and worsening PROMIS scores with worsening disease (P < .001 for all comparisons). CONCLUSIONS: In a cross-sectional and longitudinal study, we observed differences between patients with IBD and the general population in several important aspects of health. The improvement in diverse health outcome measures with improved disease control provides strong support for the construct validity of PROMIS measures in the IBD population. Their use should advance patient-centered outcomes research in IBD.
Authors: Lesley A Graff; Norah Vincent; John R Walker; Ian Clara; Rachel Carr; Jason Ediger; Norine Miller; Linda Rogala; Patricia Rawsthorne; Lisa Lix; Charles N Bernstein Journal: Inflamm Bowel Dis Date: 2010-12-22 Impact factor: 5.325
Authors: Kelvin Thia; William A Faubion; Edward V Loftus; Tore Persson; Anders Persson; William J Sandborn Journal: Inflamm Bowel Dis Date: 2011-01 Impact factor: 5.325
Authors: Lisa M Lix; Tolulope T Sajobi; Richard Sawatzky; Juxin Liu; Nancy E Mayo; Yuhui Huang; Lesley A Graff; John R Walker; Jason Ediger; Ian Clara; Kathryn Sexton; Rachel Carr; Charles N Bernstein Journal: Qual Life Res Date: 2012-06-15 Impact factor: 4.147
Authors: David Cella; Susan Yount; Nan Rothrock; Richard Gershon; Karon Cook; Bryce Reeve; Deborah Ader; James F Fries; Bonnie Bruce; Mattias Rose Journal: Med Care Date: 2007-05 Impact factor: 2.983
Authors: Arlene E Chung; Robert S Sandler; Millie D Long; Sean Ahrens; Jessica L Burris; Christopher F Martin; Kristen Anton; Amber Robb; Thomas P Caruso; Elizabeth L Jaeger; Wenli Chen; Marshall Clark; Kelly Myers; Angela Dobes; Michael D Kappelman Journal: J Am Med Inform Assoc Date: 2016-01-28 Impact factor: 4.497
Authors: Kathryn E Flynn; Mary Amanda Dew; Li Lin; Maria Fawzy; Felicia L Graham; Elizabeth A Hahn; Ron D Hays; Robert L Kormos; Honghu Liu; Mary McNulty; Kevin P Weinfurt Journal: Qual Life Res Date: 2015-06-03 Impact factor: 4.147
Authors: Edward L Barnes; Bharati Kochar; Millie D Long; Michael D Kappelman; Christopher F Martin; Joshua R Korzenik; Seth D Crockett Journal: Inflamm Bowel Dis Date: 2017-06 Impact factor: 5.325
Authors: Edward L Barnes; Hans H Herfarth; Robert S Sandler; Wenli Chen; Elizabeth Jaeger; Van M Nguyen; Amber R Robb; Michael D Kappelman; Christopher F Martin; Millie D Long Journal: Inflamm Bowel Dis Date: 2017-07 Impact factor: 5.325
Authors: Marina Arvanitis; Darren A DeWalt; Christopher F Martin; Millie D Long; Wenli Chen; Beth Jaeger; Robert S Sandler; Michael D Kappelman Journal: J Pediatr Date: 2016-05-02 Impact factor: 4.406
Authors: Maisa I Abdalla; Robert S Sandler; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Millie D Long Journal: Inflamm Bowel Dis Date: 2016-11 Impact factor: 5.325
Authors: Bharati Kochar; Christopher F Martin; Michael D Kappelman; Brennan M Spiegel; Wenli Chen; Robert S Sandler; Millie D Long Journal: Am J Gastroenterol Date: 2017-08-29 Impact factor: 10.864
Authors: Matthew Geisz; Christina Ha; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Robert S Sandler; Millie D Long Journal: Inflamm Bowel Dis Date: 2016-06 Impact factor: 5.325